Teijin Pharma and Scynexis Sign Research Agreement
News Oct 14, 2005
Teijin Pharma Limited, a wholly owned subsidiary of Teijin Limited, and Scynexis have signed an agreement under which Scynexis will provide comprehensive medicinal and analytical chemistry services to Teijin Pharma's research programs.
The agreement provides Teijin Pharma with dedicated chemistry resources including a highly experienced Scynexis medicinal chemistry team backed by proprietary, innovative technologies.
“Scynexis is pleased to work with Teijin Pharma in its novel drug discovery and development efforts and to have Teijin Pharma as one of Scynexis' valued customers in the important Japanese market,” said Yves Ribeill, President and Chief Executive Officer of Scynexis.
“Scynexis has now firmly established relationships in Japan, Europe and the U.S. confirming its ability to deliver valuable capabilities and technologies to a wide range of customers.”
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE